Relapsed/refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.
Reversible, selective isocitrate dehydrogenase-2 enzyme (IDH2) inhibitor. Inhibits mutant IDH2 enzyme, which decreases 2-hydroxyglutarate (2-HG) levels and induces myeloid differentiation in vitro.
100 mg PO once daily with or without food until disease progression or unacceptable toxicity.
Approval was based on a phase 1/2 study (AG221-C-001) that enrolled 199 patients with relapsed/refractory AML treated with enasidenib. The median overall survival (OS) with enasidenib was 9.3 months. In those achieving a complete response (CR), the median OS was 19.7 months, and in the non-CR responders, the median OS was 13.8 months. In those without a response, the median OS was 7 months.
Medscape © 2018 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Mary L Windle. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review - Medscape - Jan 11, 2018.